NurOwn cell therapy led to significant improvements in the physical abilities, vision, and cognition of people withprogressive multiple sclerosis (MS) in a Phase 2 clinical trial, top-line data show.
In addition to these positive efficacy results, BrainStorm Cell Therapeutics, NurOwns developer, announced that its cell-based therapy showed a good overall safety profile.
Trial participants received three injections, with two-month intervals between each treatment. The company reported that levels of neuroprotective molecules increased in the treated MS patients while neuroinflammatory biomarkers decreased.
This is an extremely exciting outcome, as it demonstrates the potential of our proprietary cell therapy NurOwn in progressive MS and expands the body of evidence supporting the NurOwn technology platform in neurodegenerative disease, Chaim Lebovits, CEO of BrainStorm, said in a press release.
NurOwn is produced from a patients own bone marrow-derived mesenchymal stem cells (MSCs). MSCs are grown under specific conditions that stimulate cells to release neurotrophic factors (NTFs). These factors induce the growth and development of brain cells.
MSC-NTF cells are designed to deliver NTFs and other important factors directly to the site of damage to slow the progression of the disease.
Brainstorm evaluated the safety and efficacy of NurOwn in progressive MS in a Phase 2, open-label, multicenter trial (NCT03799718).
Altogether, 20 primary and secondary progressive MS patients, ranging in age from 18 to 65, were enrolled in the trial. All patients could walk 25 feet in 60 seconds (one minute) or less and had not relapsed within six months of enrollment. The average age of the group was 47, and a majority of the participants (56%) were female.
Participants were allowed to be on a stable dose of disease-modifying therapy during the trial.
Three injections of 100-125 million MSC-NTF cells were given intrathecally, or directly into the spinal canal. There were two-month intervals between each treatment, and patients were followed for a total of 28 weeks (about seven months) after the first injection.
The primary endpoint, or goal, of the trial was safety, and the second endpoint was efficacy.
In total, 18 of 20 patients were treated with NurOwn, and of these, 16 (80%) completed the trial. Two of the 18 patients dropped out of the study because of adverse events (AEs) or side effects caused by the procedure.
There were no deaths related to the study or AEs due to worsening of MS symptoms.
For efficacy, the trials data were compared with those of 48 matched patients from a clinical group involved in the Comprehensive Longitudinal Investigations in MS study, known as CLIMB, done at the Brigham & Womans Hospital in Boston.
Several tests were performed to evaluate the patients functional, mental and visual abilities. These were the 9-hole peg test (9-HPT), the timed 25-foot walk (T25-FW), the 12-item MS Walking Scale (MSWS-12), the Symbol Digit Modality Test (SDMT), and an eye exam known as Low Contrast Letter Acuity (LCLA).
Among the NurOwn-treated patients, 14% showed prespecified 25% improvements in the T25-FW by 28 weeks. Likewise, 13% of MS patients treated with NurOwn showed improvements by 25% in the 9-HPT. None of the matched controls in the CLIMB registry showed improvements in these measures.
NurOwn-treated patients also showed an average improvement of 10% in T25-FW and 4.8% on the 9-HPT, in comparison with their performance prior to treatment. In contrast, in matched controls from the CLIMB registry, a worsening of 1.8% in T25-FW, and 1.4% on 9-HPT, were observed.
A minimum of a 10-point improvement was obtained by 38% of NurOwn-treated patients on the MSWS-12, a patient self-assessment survey that evaluates walking ability. By the end of the 28-week study, treated patients showed a 6% improvement in MSWS-12 compared with the start of the study.
Furthermore, 47% of NurOwn-treated patients achieved a minimum of an eight-letter improvement in the vision test, known as LCLA, while 67% showed at least a three-point improvement in the cognitive processing speed test SDMT.
Biomarkers from the cerebrospinal fluid (CSF) were analyzed before each NurOwn injection. While levels of molecules with neuroprotective effects such as VEGF and HGF increased, proteins associated with neuroinflammation namely MCP-1, SDF-1, and osteopontin decreased.
These positive results indicate the potential of MSC-NTF cells to lessen inflammatory mechanisms, promote repair, and restore function in progressive MS, a condition for which there is great need for effective therapy, said Jeffrey Cohen, MD, director of experimental therapeutics at the Cleveland Clinic Mellen Center for MS.
The unprecedented results of this phase 2 clinical trial provide strong support for the potential of NurOwn to address the unmet clinical and biological need in progressive MS, said Ralph Kern, MD, president and chief medical officer of Brainstorm.
Currently, few therapeutic options exist to address the relentless clinical progression and disability accumulation, ongoing compartmentalized and intrathecal CNS inflammation, and progressive loss of neural function in progressive MS, Kern said.
Brainstorm plans to present its findings on efficacy and biomarker analyses at an upcoming scientific meeting and to publish the results in a peer-reviewed journal.
The company received a grant from the National MS Society to support this Phase 2 clinical trial testing NurOwn in patients with progressive MS. Of note, the company also is testing NurOwn as a therapy for amyotrophic lateral sclerosis.
We applaud Brainstorm for completion of this first in human trial of NurOwn in progressive MS, and are encouraged by the early indication of safety and effectiveness, said Mark Allegretta, PhD, vice president of research at the National MS Society. Were hopeful that our collaboration will uncover insights into clinically relevant biomarkers that may predict a treatment effect in progressive MS.
Total Posts: 1,053
Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
Read more from the original source:
- FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz IND for Stroke Treatment - KPVI News 6 - May 14th, 2021
- Duluth health center specializes in regenerative medicine, hormone replacement therapy - Duluth News Tribune - May 14th, 2021
- Dr. Krger on Toxicities Associated With Allogeneic Stem Cell Transplant in Myeloma - OncLive - May 14th, 2021
- Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its... - May 14th, 2021
- Genenta Phase I/II Glioblastoma Data at ASGCT Show Temferon Delivered Tumor-Focused Interferon ExpressionData presented at the 2021 American Society... - May 14th, 2021
- ViaCyte To Participate In World Medical Innovation Forum Panel On Future Of Cell Therapy For Type 1 Diabetes - PRNewswire - May 14th, 2021
- Omeros' Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress - Business Wire - May 14th, 2021
- Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May - Business Wire - May 14th, 2021
- Outlook for multiple myeloma: Figures and factors that affect it - Medical News Today - May 14th, 2021
- Global Regenerative Medicine for Cartilage Market Report 2021: Companies are Continuously Focusing on Introducing New Technologies to Survive in the... - May 14th, 2021
- UB celebrates 175th anniversary of its origins in study of medicine - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter - May 14th, 2021
- Stem cell therapy for COVID-19 and ARDS - News-Medical.Net - May 7th, 2021
- Experimental COVID-19 lung treatment being tested at Ontario hospitals - CityNews Toronto - May 7th, 2021
- EP. 4: Optimizing Patient Selection for CAR T-Cell Therapy - OncLive - May 7th, 2021
- Could stem cells improve the outcome of ARDS in severe COVID-19? - News-Medical.Net - May 7th, 2021
- Motixafortide Reaches Primary End Point of Improved Stem Cell Mobilization in Multiple Myeloma Trial - Cancer Network - May 7th, 2021
- Restricting the Growth and Spread of Head and Neck Cancers - Technology Networks - May 7th, 2021
- The global stem cell therapy market is projected to reach USD 401 million by 2026 from - GlobeNewswire - May 7th, 2021
- UCLA team discovers how to restrict growth, spread of head and neck cancers | UCLA - UCLA Newsroom - May 7th, 2021
- NUS scientists found a key element that affects how genes are expressed in blood stem cells - Newswise - May 7th, 2021
- Citius Pharmaceuticals to Present Mino-Lok and COVID-related Respiratory Treatment Update at Benzinga Global Small Cap Conference on Thursday, May 13... - May 7th, 2021
- Mesoblast says its stem cell treatment saved lives of severely ill COVID patients - Stockhead - May 2nd, 2021
- Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants - News-Medical.Net - May 2nd, 2021
- Antiviral T cells protected, viable as off-the-shelf treatment for painful complication stem cells - Microbioz India - May 2nd, 2021
- Desperate family of boy, 9, with leukaemia have 10 days to save his life... - The Sun - May 2nd, 2021
- Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy - GlobeNewswire - May 2nd, 2021
- Investigating CAR T-Cell Therapy for Use in Different Disease Types - Targeted Oncology - May 2nd, 2021
- Enhanced inhibition of tumor growth using TRAIL-overexpressing adipose-derived stem cells in combination with the chemotherapeutic agent CPT-11 in... - May 2nd, 2021
- Thomas Smeenk on Hemostemix's autologous stem cell therapy technology and why some call it 'the fountain of youth' - InvestorIntel - April 28th, 2021
- Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer... - April 28th, 2021
- Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting - GlobeNewswire - April 28th, 2021
- Therapeutic Solutions International Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low... - April 28th, 2021
- A review of baculovirus vectors in gene therapy | BTT - Dove Medical Press - April 28th, 2021
- Stem Cell Therapy for COPD: Hope and Exploitation - DocWire News - April 26th, 2021
- Axion BioSystems Announces Formation of Scientific Advisory Board - Business Wire - April 26th, 2021
- Global Cell Therapy Market By Therapy Type, By Therapeutic Area, By End User, By Cell Type, By Regional Outlook, Industry Analysis Report and... - April 24th, 2021
- Pure Red Cell Aplasia following ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation: Resolution with Daratumumab Treatment - DocWire... - April 24th, 2021
- Advancing the Development of Safe and Effective Regenerative Medicine Products | FDA - FDA.gov - April 24th, 2021
- New method helps map the specialized diversity and spatial location of cells within a tissue or tumor - News-Medical.Net - April 24th, 2021
- Chimeric embryo may have medical implications The Campus - The Campus - April 24th, 2021
- Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National... - April 24th, 2021
- Guenther Koehne, MD, Highlights Recent Advancements in the Treatment of Blood Cancers - Oncology Learning Network - April 24th, 2021
- Rinri Therapeutics raises 10 million to advance stem cell therapy for hearing loss - The Star - April 24th, 2021
- Cancer Diagnosis in Patient Given LentiGlobin Revised to Severe Anemia - Sickle Cell Anemia News - April 24th, 2021
- Hodgkin lymphoma: Symptoms, outlook, treatment, and more - Medical News Today - April 24th, 2021
- Tissue Repair, Mitochondrial Function and Wound Healing Explored in 2021 APS Presidents Symposium - Newswise - April 24th, 2021
- Axion BioSystems Announces Formation of Scientific Advisory Board - BioSpace - April 20th, 2021
- Avalon GloboCare is seeking to tap the power of cells to fight cancer and coronavirus - Proactive Investors USA - April 20th, 2021
- Rinri Therapeutics Raises 10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss -... - April 20th, 2021
- Global Regenerative Medicines Market 2020-2030: Opportunities in Drug Approvals and Strong Pipeline of Cell and Gene Therapies & Multiple... - April 20th, 2021
- FDA Grants Orphan Drug Status to Novel IRAK4 Inhibitor in AML and MDS - Targeted Oncology - April 20th, 2021
- Vertex Drops $900 Million to Expand Partnership with CRISPR Therapeutics - BioSpace - April 20th, 2021
- Kaleido Biosciences Announces Collaboration with Robert Jenq, MD, to Explore Potential of its Microbiome Metabolic Therapies (MMT) in Preventing... - April 20th, 2021
- Partner Content | Being bionic: the future of regenerative medicine - TheSpec.com - April 14th, 2021
- Ohio State Recruits Top Oncologist to Expand Cell Therapy Program, Lead Bone Marrow Transplant Services - Wexner Medical Center - The Ohio State... - April 14th, 2021
- Leukemia Cutis: Symptoms and Treatment - Healthline - April 14th, 2021
- Green: Variants and outbreaks continue to put stress on hospitals - Vermont Biz - April 14th, 2021
- CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends - GlobeNewswire - April 14th, 2021
- Consortium to investigate role of neurofilament light chain in neurodegenerative diseases Washington University School of Medicine in St. Louis -... - April 14th, 2021
- Man's heart healed by stem cell therapy and love of an old flame - Leeds Live - April 12th, 2021
- New pediatric cancer treatment method being used in Iran - Tehran Times - April 12th, 2021
- Personalized Cancer Vaccine Shows Early Efficacy in Patients With Diverse Tumor Types - Technology Networks - April 12th, 2021
- 1000th Stem Cell Transplant Given to Girl Who Is One in a Million - Stanford Children's Health Blog - Stanford Children's Health - April 10th, 2021
- Home : Stem Cell Treatments - April 10th, 2021
- Researchers discover unique regenerative property of cells in the early human embryo - News-Medical.net - April 10th, 2021
- Study reveals sex-differences in aging of the brain stem cell niche - News-Medical.net - April 10th, 2021
- Antibiotics need further study in cancer treatments - Chicago Daily Herald - April 10th, 2021
- Prolonged infection and inflammation drain immune responses as we age - Baylor College of Medicine News - April 10th, 2021
- Toward a transformative therapy for sickle cell patients - News-Medical.Net - April 10th, 2021
- Mass. Residents 55+ Or With 1 Medical Condition Can Now Get COVID Vaccine | WBZ NewsRadio 1030 - iHeartRadio - April 6th, 2021
- Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - DocWire News - April 6th, 2021
- BioRestorative Therapies Announces Appointment of Nickolay V. Kukekov, Ph.D to its Board of Directors - BioSpace - April 6th, 2021
- LGL Leukemia: Overview, Symptoms, and Treatment - Healthline - April 3rd, 2021
- Novel T-Cell Therapy MT-401 Under Evaluation in Post-Transplant AML - OncLive - April 3rd, 2021
- Funding the Next Generation of Cancer Therapies - Genetic Engineering & Biotechnology News - April 3rd, 2021
- Do Therapies for Alzheimer's & Parkinson's that Clear Abnormal Brain Proteins Make the Diseases Worse? - BioSpace - April 3rd, 2021
- Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy - DocWire News - April 1st, 2021
- Insulin 100: How the road to a diabetes cure is yielding better treatments - News@UofT - April 1st, 2021
- The Government's Watchful Eye on Fraud Stemming from Stem Cell Therapy - Lexology - April 1st, 2021
- Introducing a neuro regenerative gene into mice with spinal cord injury improves motor function - News-Medical.net - April 1st, 2021